Table 2.
Microarray studies in which high levels of expression of CRYAB, TKTL1, HSPB2 or CYP1B1 is significantly associated with poorer outcome in ovarian cancer patients
| Gene | Dataset | Cancer type | Endpoint | Cohort | Contributor | Array type | Probe ID | N | Cutpoint | Minimum value |
Corrected value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TKTL1 | GSE14764 | Ovarian cancer | Overall survival | TOC | Denkert | HG-U133A | 216370_s_at | 80 | 0.56 | 0.000197 | 0.006343 |
| HSPB2 | GSE26712 | Ovarian cancer | Disease free survival | MSKCC (1990–2003) | Bonome | HG-U133_Plus_2 | 205824_at | 185 | 0.80 | 0.001782 | 0.030984 |
| HSPB2 | DUKE-OC | Ovarian cancer | Overall survival | Duke | Bild | HG-U133A | 205824_at | 133 | 0.71 | 0 | 0 |
| HSPB2 | GSE9891 | Ovarian cancer | Overall survival | AOCS, RBH, WH, NKI-AVL (1992–2006) | Tothill | HG-U133_Plus_2 | 205824_at | 278 | 0.73 | 0.001263 | 0.041191 |
| CRYAB | GSE9891 | Ovarian cancer | Overall survival | AOCS, RBH, WH, NKI-AVL (1992–2006) | Tothill | HG-U133_Plus_2 | 209283_at | 278 | 0.65 | 0.000346 | 0.01033 |
| CRYAB | DUKE-OC | Ovarian cancer | Overall survival | Duke | Bild | HG-U133A | 209283_at | 133 | 0.76 | 0.000052 | 0.001972 |
| CRYAB | GSE8841 | Ovarian cancer | Overall survival | Milan (1992–2003) | Marchini | G4100A | 5559 | 81 | 0.85 | 0.000088 | 0.003139 |
| CRYAB | GSE8841 | Ovarian cancer | Overall survival | Milan (1992–2003) | Marchini | G4100A | 1818 | 81 | 0.78 | 0.000222 | 0.007027 |
| CRYAB | GSE17260 | Ovarian cancer | Progression free survival | Niigata (1997–2008) | Yoshihara | G4112A | A_24_P206776 | 110 | 0.89 | 0.000642 | 0.017534 |
| CYP1B1 | DUKE-OC | Ovarian cancer | Overall survival | Duke | Bild | HG-U133A | 202436_s_at | 133 | 0.86 | 0.001277 | 0.031267 |
| CYP1B1 | DUKE-OC | Ovarian cancer | Overall survival | Duke | Bild | HG-U133A | 202437_s_at | 133 | 0.83 | 0.001997 | 0.045241 |